A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK1362885 in Type 2 Diabetics
Status:
Completed
Trial end date:
2009-11-20
Target enrollment:
Participant gender:
Summary
This study is the second administration of GSK1362885 in humans. GSK1362885 is a novel,
potent inhibitor of human glycogen phosphorylase (GP) under development for the treatment of
type 2 diabetes mellitus (T2DM). This study will investigate the compound's safety,
tolerability, pharmacokinetics, and pharmacodynamics in subjects with Type 2 Diabetes
Mellitus.